Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 5/20 | 0.44 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.41 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.40 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 2/20 | 0.39 |
| ▸ | CES1 | P23141 | 2/20 | 0.39 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22796814 | 0.85 | CES2 (0.42) | KCNN4PDK1PDK2PDK3PDK4 | |
| SCHEMBL1822203 | 0.84 | KCNN4 (0.49) | KCNN4PDK1PDK2PDK3PDK4 | |
| SCHEMBL8906107 | 0.82 | KCNN4 (0.43) | KCNN4PDK1PDK2PDK3PDK4 | |
| SCHEMBL12841736 | 0.82 | KCNN4 (0.46) | KCNN4PDK1PDK2PDK3PDK4 | |
| SCHEMBL8915396 | 0.79 | KCNN4 (0.41) | KCNN4PDK1PDK2PDK3PDK4 | |
| SCHEMBL888782 | 0.79 | KCNN4 (0.41) | KCNN4PDK1PDK2PDK3PDK4 | |
| SCHEMBL31612947 | 0.79 | NPSR1 (0.44) | KCNN4PDK1PDK2PDK3PDK4 | |
| SCHEMBL19578179 | 0.79 | KCNN4 (0.41) | KCNN4PDK1PDK2PDK3PDK4 | |
| SCHEMBL19578315 | 0.79 | KCNN4 (0.41) | KCNN4PDK1PDK2PDK3PDK4 | |
| SCHEMBL18117413 | 0.78 | KCNN4 (0.47) | KCNN4PDK1PDK2PDK3PDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752611-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-10017499-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170320833-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-09 | — | — | US | disclosed |
| US-9765087-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-9758487-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-12 | — | — | US | disclosed |
| US-9676802-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20170114046-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARM INC (US) | 2017-04-27 | — | — | US | disclosed |
| US-20160311778-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2016-10-27 | — | — | US | disclosed |
| US-9421192-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-08-23 | — | — | US | disclosed |
| US-20160067223-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-03-10 | — | — | US | disclosed |
| US-20110008288-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-01-13 | — | — | US | disclosed |
| US-20100266543-A1 | LINKED DIBENZIMIDAZOLE ANTIVIRALS | ENANTA PHARMACEUTICALS, INC. | 2010-10-21 | — | — | US | disclosed |
| US-20100260715-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2010-10-14 | — | — | US | disclosed |
| US-20100233122-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-16 | — | — | US | disclosed |
| US-20100226882-A1 | LINKED DIIMIDAZOLE ANTIVIRALS | ENANTA PHARMACEUTICALS, INC. | 2010-09-09 | — | — | US | disclosed |
| US-20100221216-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2010-09-02 | — | — | US | disclosed |
| US-20100221215-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-02 | — | — | US | disclosed |
| US-20100158862-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-06-24 | — | — | US | disclosed |
| US-20090068140-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-03-12 | — | — | US | disclosed |
| US-20080050336-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114046-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | KCNN4 4631/4885PDK1 642/4885PDK2 984/4885 |
| US-20100226882-A1 | LINKED DIIMIDAZOLE ANTIVIRALS | EIF2AK2, ZC3HAV1, MAVS | KCNN4 4457/4885PDK1 1181/4885PDK2 1232/4885 |
| US-20160067223-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | KCNN4 4880/4885PDK1 1514/4885PDK2 2564/4885 |
| US-20100260715-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | KCNN4 4832/4885PDK1 1716/4885PDK2 2746/4885 |
| US-20100233122-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | KCNN4 4631/4885PDK1 642/4885PDK2 984/4885 |
| US-20080050336-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | KCNN4 4880/4885PDK1 1514/4885PDK2 2564/4885 |
| US-20090068140-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | KCNN4 4880/4885PDK1 1514/4885PDK2 2564/4885 |
| US-20100221215-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | EIF2AK2, NSUN2, ZC3HAV1 | KCNN4 4776/4885PDK1 923/4885PDK2 1527/4885 |
| US-10017499-B2 | Benzimidazole derivatives | EIF2AK2, ZC3HAV1, ZC3HAV1L | KCNN4 4536/4885PDK1 680/4885PDK2 975/4885 |
| US-20110008288-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | KCNN4 4832/4885PDK1 1716/4885PDK2 2746/4885 |
| US-20100266543-A1 | LINKED DIBENZIMIDAZOLE ANTIVIRALS | EIF2AK2, ZC3HAV1, NSUN2 | KCNN4 4716/4885PDK1 1069/4885PDK2 1675/4885 |
| US-20170320833-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | KCNN4 4880/4885PDK1 1514/4885PDK2 2564/4885 |
| US-20100221216-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | KCNN4 4832/4885PDK1 1716/4885PDK2 2746/4885 |
| US-20160311778-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | KCNN4 4880/4885PDK1 1514/4885PDK2 2564/4885 |
| US-20100158862-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | KCNN4 4880/4885PDK1 1514/4885PDK2 2564/4885 |
| US-10752611-B2 | Benzimidazole derivatives | EIF2AK2, ZC3HAV1, ZC3HAV1L | KCNN4 4536/4885PDK1 680/4885PDK2 975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.